<DOC>
	<DOCNO>NCT00618956</DOCNO>
	<brief_summary>The study design accurately assess change blood pressure pulse 100 200 mg daily dose milnacipran patient fibromyalgia syndrome .</brief_summary>
	<brief_title>A Study Of Milnacipran In Patients With Fibromyalgia : Effects On 24 Hour Ambulatory Blood Pressure Monitoring</brief_title>
	<detailed_description>This study double blind ( neither physician know receive active study drug placebo , inactive compound sugar pill ) conduct various research center United States . If study staff determines eligible decide participate , approximately 11 study visit 3 month . During visit , undergo routine health exam complete different kind questionnaire . This study require wear blood pressure cuff continuously 24 hour three separate occasion . You also require make multiple same-day visit study site three separate occasion blood draw .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>To eligible participate study , patient must meet following criterion : 1 . Patients may male female age 18 70 year , inclusive 2 . Patients must diagnose primary fibromyalgia , define 1990 ACR Criteria Classification Fibromyalgia 3 . Females must either postmenopausal ( menses least 1 year ) , posthysterectomy , postoophorectomy ( bilateral ) , , childbearing potential , must negative urine pregnancy test prior randomization use medically acceptable form contraception ( eg , hormonal birth control , IUD , doublebarrier method [ eg , simultaneous use two following : male condom , female condom , diaphragm ] , barrier method plus spermicidal agent [ contraceptive foam , jelly , cream ] ) 4 . Patients must ability give write informed consent 5 . Patients may hypertension untreated treat maximum two antihypertensive medication . ( Note : medication contribute combination product ( ) consider separate medication . ) If untreated , patient stable , expectation initiate treatment study . If treat , patient must stable dos antihypertensive medication least 2 month , expectation dose adjustment necessary duration study . A patient classify hypertensive patient take antihypertensive medication , SBP equal great 130 mm Hg , DBP equal great 85 mm Hg . A patient classify normotensive he/she antihypertensive medication SBP le 130 mm Hg DBP le 85 mm Hg 6 . Patients must mean two sit SBP measurement less 160 mm Hg sit DBP le 100 mm Hg Visit 1 ( Screening ) Visit 2 ( Baseline/Randomization ) use automatic office blood pressure monitor 7 . Patients must normal physical examination finding , clinical laboratory result , electrocardiogram ( ECG ) result Visit 1 ( Screening ) abnormal finding judge clinically significant Investigator document eCRF 8 . Patients must willing withdraw CNSactive therapy market antidepressant , include monoamine oxidase inhibitor , tricyclic , tetracyclics , selectiveserotonin reuptake inhibitor ( SSRIs ) , noradrenaline reuptake inhibitor ( NARIs ) , noradrenalineserotonin reuptake inhibitor ( NSRI ) , serotoninnoradrenaline reuptake inhibitor ( SNRIs ) , St. John 's Wort 9 . Patients must willing withdraw pregabalin ( Lyrica ) gabapentin ( Neurontin ) . 10 . Patients must willing withdraw stimulant medication use treat attention deficit disorder/attention deficit hyperactivity disorder ( eg , amphetamine/dextroamphetamine [ Adderall ] , methylphenidate , dextroamphetamine ) fatigue associate sleep apnea shift work ( eg , modafinil ) 11 . Patients must willing withdraw anorectic agent diethylpropion , sibutramine ( Meridia ) , phentermine ( Adipex ) 12 . Patients must willing withhold certain medication 24 hour , well , ABPM assessment . These medication include phosphodiesterase type 5 inhibitor ( eg , Viagra , Levitra , Cialis , Edex , Muse ) , decongestant ( eg , pseudoephedrine , phenylephrine ) , antimigraine therapy ( eg , triptans Imitrex Maxalt , ergotamines Cafergot Midrin ) . If , reason , patient take medication , ABPM visit reschedule least 24 hour transpire since patient 's last use Patients meet follow criterion eligible participate study : Psychological/Psychiatric Criteria 1 . Patients significant risk suicide , accord Investigator 's judgment base answer 2 3 question 9 Beck Depression Inventory ( BDI ) ( regard suicidal ideation ) perform Visit 1 ( Screening ) Visit 2 ( Baseline/Randomization ) 2 . Patients total BDI score great 25 Visit 1 ( Screening ) Visit 2 ( Baseline/Randomization ) 3 . Patients test positive illegal substance prior Visit 2 ( Baseline/Randomization ) demonstrate positive drug screen base Investigator 's judgment 4 . Patients history behavior would , Investigator 's judgment , prohibit compliance duration study Somatic Criteria 1 . Patients myocardial infarction and/or stroke within past 12 month ; active cardiac disease ( American Heart Association Functional Class 2 , 3 , 4 ) ; congestive heart failure ; hemodynamically significant valvular heart disease ( include patient prosthetic heart valve ) ; hypertensive cardiovascular disease change ( heart , eye kidney ) Investigator 's judgment , would preclude patient participation ; ischemic change ; and/or clinically significant cardiac rhythm conduction abnormality ( include atrial fibrillation , leave bundle branch block , second thirddegree heart block ) 2 . Patients mean two sit systolic blood pressure ( SBP ) read equal great 160 mm Hg sit diastolic blood pressure ( DBP ) equal great 100 mm Hg Visits 1 ( Screening ) 2 ( Baseline/Randomization ) use automatic office blood pressure monitor 3 . Patients pacemaker 4 . Patients upper arm circumference le 24 cm great 42 cm nondominant arm 5 . Patients evidence active liver disease ( level aspartate aminotransferase , alanine aminotransferase , and/or alkaline phosphatase &gt; 1.5Ã— upper limit normal range clinical laboratory perform test ) 6 . Patients renal impairment ( estimate creatinine clearance &lt; 50 mL/min ) 7 . Patients document autoimmune disease . Patients diagnose Hashimoto Grave disease stable 3 month prior Visit 1 ( Screening ) allow enroll 8 . Patients current systemic infection ( eg , human immunodeficiency virus , hepatitis ) 9 . Patients active cancer , except basal cell carcinoma . Patients take prophylactic tamoxifen ( antiestrogen agent ) family history breast cancer patient take tamoxifen ( antiestrogen agent ) least 1 year postactive treatment breast cancer , may enrol 10 . Patients current life expectancy le 1 year 11 . Patients active peptic ulcer disease history inflammatory bowel disease celiac sprue 12 . Patients pulmonary dysfunction severe chronic obstructive pulmonary disease , Investigator 's judgment , could interfere study participation completion 13 . Patients unstable endocrine disease , include unstable diabetes thyroid disease . Disorders stable precede 3 month acceptable 14 . Male patient prostatic enlargement genitourinary disorder might significant risk dysuria and/or urinary retention take agent noradrenalinereuptake inhibition property 15 . Pregnant breastfeeding patient 16 . Any condition ( epilepsy ) , Investigator 's judgment , would indicate patient unsuitable study ( eg , might interfere study conduct , confound interpretation study result , endanger patient ) TreatmentRelated Criteria 1 . Patients receive treatment experimental agent within last 30 day prior Visit 1 ( Screening ) . Patients complete previous milnacipran study ( ie , respective protocolrelated study procedure complete patient ) eligible participate . Any patient fail screen previous milnacipran study may reevaluate , eligible patient may enroll . Patients currently enrol Study MLNMD06 eligible participate 2 . Patients receive concomitant therapy digitalis ( digoxin ) preparation . ( Note : Patients undergo washout digoxin ; therefore , patient digoxin enrol study ) 3 . Patients receive concomitant therapy monoamine oxidase inhibitor , tricyclic , tetracyclics , SSRIs , noradrenaline noradrenalineserotonin ( NSRI ) reuptake inhibitor , SNRIs , St. John 's Wort , and/or agent market antidepressant unable washout washout inadvisable* 4 . Patients receive concomitant therapy pregabalin ( Lyrica ) gabapentin ( Neurontin ) unable washout washout inadvisable* 5 . Patients receive concomitant therapy stimulant medication use treat attention deficit disorder/attention deficit hyperactivity disorder ( eg , amphetamine/dextroamphetamine [ Adderall ] , methylphenidate , dextroamphetamine ) fatigue associate sleep apnea shift work ( eg , modafinil ) unable washout washout inadvisable* 6 . Patients receive concomitant therapy anorectic agent diethylpropion , sibutramine ( Meridia ) , phentermine ( Adipex ) unable washout washout inadvisable* 7 . Patients require use agent affect serotonin pharmacology , ondansetron ( Zofran ) , granisetron ( Kytril ) , and/or dolasetron ( Anzemet ) 8 . Patients require dos guaifenesin great 2400 mg/d ( approximately 24 teaspoon ) Occupational Criteria 1 . Patients whose occupation require work nocturnal hour ( eg , 11 PM 7 AM ) ABPM Criteria 1 . Patients whose ABPM result Visit 2 ( Baseline/Randomization ) satisfy ABPM inclusion/exclusion criterion outline ABPM train manual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>NSRI</keyword>
	<keyword>milnacipran</keyword>
	<keyword>fibromyalgia</keyword>
	<keyword>blood pressure</keyword>
	<keyword>hypertension</keyword>
</DOC>